PHAT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Phathom Pharmaceuticals Inc (PHAT) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has shown significant revenue growth, its financials remain weak with declining net income and EPS. Technical indicators are mixed, and no strong proprietary trading signals are present. The options data indicates some market interest, but it is not compelling enough to justify immediate action. Analysts have raised price targets, but the stock's current pre-market decline and lack of significant positive catalysts suggest holding off for now.
The MACD is positive and expanding, indicating bullish momentum, but the RSI is neutral at 56.737. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near its resistance level of 11.532. Overall, the technical indicators are mixed, with no clear buy signal.
The company aims to achieve profitability by early Q3 2026, which could be a long-term positive catalyst.
The company's financial performance shows a significant drop in net income (-71.59% YoY) and EPS (-72.38% YoY). Gross margin has also slightly declined. Additionally, the pre-market price is down by 0.54%, and there are no significant insider or hedge fund trading trends.
In Q4 2025, revenue increased by 94.12% YoY to $57.58M, but net income dropped by 71.59% YoY to -$21.15M. EPS fell by 72.38% YoY to -0.29, and gross margin slightly declined to 86.72%. The company is not yet profitable.
Guggenheim maintains a Buy rating with a price target of $25, while Goldman Sachs has a Neutral rating with a price target of $13. Analysts are cautiously optimistic but highlight uncertainties around regulatory exclusivity and marketing campaigns.
